Pharmaceutical giant Astellas Pharma Inc. has signed several research collaborations, including deals with Poseida Therapeutics, Invenra Inc. for bispecific antibody discovery, and Vivtex. Despite a decrease in short interest by 10.5% in June, the company is receiving high attention from institutional owners, holding 59% of the firm. Astellas is also broadening its oncological portfolio, showcased at the 2024 ASCO Annual Meeting.
Furthermore, it made significant strides in the cell therapy ecosystem through partnering with YASKAWA. The U.S. FDA has acknowledged the resubmission of Astellas's Biologics License Application for Zolbetuximab, while it has also secured approvals for several drugs, including its gastric cancer antibody in Japan, and for high-risk prostate cancer in Europe. However, FDA rejected its gastric cancer drug application due to manufacturing issues. Notably, the company is seeking to increase investment in a new state-of-the-art facility in Ireland, indicating potential further growth in its pipeline.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Tue, 16 Jul 2024 10:54:07 GMT - Rating 6 - Innovation 6 - Information 9 - Rumor 7
